ReproCELL

Symic Biomedical, based in San Francisco, California, is a biotechnology company founded in 2012 that focuses on developing matrix regulator therapeutics. These therapeutics are designed to target and bind to matrix structures that are damaged due to injury or disease, thereby inhibiting pathological inflammatory responses. The company's research primarily addresses treatments for osteoarthritis and cardiovascular conditions, while also exploring applications in fibrosis, oncology, and diseases affecting the central nervous system. As a subsidiary of Symic Holdings, LLC, Symic Biomedical aims to provide innovative solutions in the healthcare sector through its specialized technology.

BioServe Biotechnologies (India) Pvt Ltd, established in 1994 and based in Hyderabad, specializes in providing a comprehensive range of molecular services and research tools. The company offers DNA extraction, synthesis, sequencing, and testing services, including next-generation sequencing, biomarker discovery, and GMO testing, catering to scientists, pharmaceutical firms, and research institutes. BioServe is recognized for its 'Biomaterial to Data' model, which enhances research in genetics, drug discovery, and molecular diagnostics. Additionally, the company develops and manufactures a variety of molecular biology kits for research and educational purposes. It is a DSIR-recognized laboratory with ISO9001-2008 and NABL accreditation, serving numerous clients, including various ICMR and CSIR institutes and prominent pharmaceutical and biotechnology companies. As of 2018, BioServe operates as a subsidiary of ReproCELL Incorporated.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company focuses on the research and development of hepatocyte growth factor (HGF) and its applications in treating various medical conditions. Kringle Pharma's HGF products aim to promote regenerative healing in liver cells and other organs, addressing acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scars. Additionally, the company develops NK4, a bi-functional molecule that serves as an HGF antagonist, inhibiting tumor cell invasion and metastasis while exhibiting antiangiogenic properties. Kringle Pharma's pipeline includes recombinant human HGF for acute renal failure and skin ulcers, as well as NK4-based therapies for cancer treatment.

Biopta Ltd. is a contract research organization that specializes in providing services to the pharmaceutical industry using functional human tissue. Founded in 2002 and based in Glasgow, United Kingdom, Biopta utilizes ethically donated residual human tissue from surgical procedures to predict drug activity prior to clinical trials. The company offers a range of services, including laboratory techniques, comparative pharmacology, clinical biopsies, and customized solutions. Its expertise encompasses various areas such as cardiac, vascular, respiratory, gastrointestinal, human absorption, skin, and genitourinary research. Additionally, Biopta maintains a catalogue of human functional tissue assays that includes standard assays for diverse applications. The company operates laboratories in Glasgow and Maryland and has been a subsidiary of ReproCELL, Inc. since December 2015.

ReInnervate Limited is a biotechnology company based in Durham, United Kingdom, founded in 2002. The company specializes in developing innovative technologies that support research in cell growth and function in vitro, particularly within the realm of stem cell biology. ReInnervate's offerings include 3D cell-culture products that allow scientists to create assays and models that closely replicate the in-vivo environment of cells. These technologies facilitate the controlled differentiation of stem cells and the formation of specific tissue types, thereby aiding in the development of diagnostics and treatments for neurodegenerative diseases.